Needham & Company Reiterate Buy Following ResMed (RMD) Investor Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Piper Jaffray Remains Bullish Following ResMed (RMD) Analyst Day; Says Recent Pullback was Overdone
June 8, 2015 9:10 AM EDTPiper Jaffray Maintains an Overweight and $80 price target on ResMed (NYSE: RMD) following an analyst day. There were no major data points from the meeting, however, analyst Matt O'Brien believes that the recent 26% pullback in the stock was overdone, and provides an attractive entry... More
